 |
11 Diseases |  |
10 Trials |
|
10 Trials |  |
362 News |  |
| 1234» |
- | Hulio (adalimumab-fkjp) / Fujifilm Kyowa Kirin Biologics, Biocon, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Hyrimoz (adalimumab-adaz) / Sandoz
Enrollment closed, Trial completion date, Trial primary completion date: Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE (clinicaltrials.gov) - Nov 18, 2024
P=N/A, N=46, Active, not recruiting, Sponsor: NHS Greater Glasgow and Clyde
Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Nov 2024 | Trial primary completion date: Jul 2024 --> Nov 2024
- Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Humira (adalimumab) / AbbVie
Effectiveness of Switching From Reference Adalimumab to Biosimilar Adalimumab-Atto in Patients With Uveitis (POSTER THEATER) - Sep 24, 2024 - Abstract #AAO2024AAO_661;
Two percent and 1.6% of patients switched to a different biologic or back to adalimumab, respectively. Conclusion Adalimumab-atto is noninferior to adalimumab in the treatment of uveitis, with a low failure rate.
- | Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Journal: A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases. (Pubmed Central) - Sep 5, 2024
Conclusion Adalimumab-atto is noninferior to adalimumab in the treatment of uveitis, with a low failure rate. In a non-medical switch scenario of RMD patients, there was no evidence for a considerable difference in ABP retention rates over 6
- | Humira (adalimumab) / AbbVie, Yuflyma (adalimumab-aaty) / Celltrion, Hikma
Journal: Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID. (Pubmed Central) - Aug 9, 2024
In a non-medical switch scenario of RMD patients, there was no evidence for a considerable difference in ABP retention rates over 6 The most commonly used drugs at inclusion were Humira
- Humira (adalimumab) / AbbVie
Experience with multiple non-medical switches between originator and biosimilars of adalimumab in patients with psoriasis (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2679;
FIGURE 1. Survival plot visualising the number of patients within each subcohort at different time points.
- Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Humira (adalimumab) / AbbVie
Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 and Adalimumab Reference Product in Patients with Plaque Psoriasis (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2470;
Results of this study demonstrated similarity for PK, efficacy, immunogenicity, and safety in patients with Ps switching 3 times between adalimumab RP and ABP 501 as compared to patients receiving continued use of adalimumab RP. These results support a demonstration of interchangeability between ABP 501 and adalimumab RP.
- || Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
PK/PD data, Journal: Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis. (Pubmed Central) - Jun 27, 2024
A simulation of dosing the etanercept biosimilar at a lower rate of every 10 days reached steady-state concentrations earlier than the usual dosing rate of every 7 days. Simulations of altered dosing intervals could form the basis for future personalised dosing studies, potentially saving costs whilst increasing efficacy.
- || leflunomide / Generic mfg.
Clinical, Retrospective data, Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis. (Pubmed Central) - Jun 26, 2024
In this economic evaluation study, the treatment sequences initiated with biosimilar DMARDs were cost-effective compared with the treatment sequence initiated with leflunomide in managing patients with RA who experienced failure with the initial methotrexate treatment. These results suggest the need to update clinical treatment guidelines for initiating biosimilars immediately after the failure of methotrexate for patients with RA.
- | Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Journal: Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis. (Pubmed Central) - Apr 24, 2024
Amgevita is safe and effective for inflammatory uveitis with non-inferiority to Humira. Significant numbers of patients requested to switch back due to side effects including injection site reactions.
- Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Humira (adalimumab) / AbbVie
Evaluating the safety and effectiveness of switching from reference product adalimumab to biosimilar adalimumab-atto in patients with inflammatory bowel disease in an integrated health care system () - Apr 9, 2024 - Abstract #AMCP2024AMCP_264;
- Abrilada (adalimumab-afzb) / Pfizer
Early Real-World Experience With Abrilada Within the Canadian Patient Population () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2169;
Significant numbers of patients requested to switch back due to side effects including injection site reactions. Results were compared to the reference adalimumab (D2E7,
- Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp, Humira (adalimumab) / AbbVie
Outcome of psoriasis patients switched from adalimumab originator to biosimilar: a retrospective, observational study () - Feb 20, 2024 - Abstract #AAD2024AAD_2896;
Background As a cost saving measure, psoriasis patients established on adalimumab originator (Humira) were switched to adalimumab biosimilar, Imraldi...31 patients were switched back to originator/alternative biosimilar (Amgevita)...Patients who successfully switched back to the originator, did not re-achieve the same disease control as before switching. Factors associated with switching failure included: male sex, higher weight, high-impact sites involvement and presence of concomitant PsA.
- | Phase classification: CAMEO: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease (clinicaltrials.gov) - Feb 15, 2024
P4, N=900, Recruiting, Sponsor: Connecticut Children's Medical Center
Factors associated with switching failure included: male sex, higher weight, high-impact sites involvement and presence of concomitant PsA. Phase classification: P --> P4
- | Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Hyrimoz (adalimumab-adaz) / Sandoz
Retrospective data, Journal: Adalimumab Biosimilar in Pediatric Inflammatory Bowel Disease: A Retrospective Study from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD). (Pubmed Central) - Feb 10, 2024
This is the first real-world study that particularly addresses the use of ADL-BioS in pediatric IBD. With high rates of treatment persistence and a low frequency of non-serious side effects, ADL-BioS seems to be effective.
- | Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Journal: Anti-tumor necrosis factor ?: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies. (Pubmed Central) - Dec 24, 2023
Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.
- Humira (adalimumab) / AbbVie, Yuflyma (adalimumab-aaty) / Celltrion, Hikma
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_1027;
Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population. Results The most commonly used drugs at inclusion were Humira
- Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp, Humira (adalimumab) / AbbVie
Prospective evaluation of the switch from adalimumab originator to different biosimilars in IBD patients : acceptability and persistance at 1 year. (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_792;
Results The most commonly used drugs at inclusion were Humira Methods From July 2020 to September 2021, we proposed for consecutive and ambulatory IBD patients on maintenance Humira
- || Enrollment status, Trial completion date, Trial primary completion date: FREE: De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease (clinicaltrials.gov) - Nov 30, 2023
P4, N=148, Enrolling by invitation, Sponsor: University Medical Center Groningen
Methods From July 2020 to September 2021, we proposed for consecutive and ambulatory IBD patients on maintenance Humira Recruiting --> Enrolling by invitation | Trial completion date: Jun 2023 --> Mar 2025 | Trial primary completion date: Jun 2023 --> Mar 2025
- | Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Journal: Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto. (Pubmed Central) - Nov 22, 2023
Recruiting --> Enrolling by invitation | Trial completion date: Jun 2023 --> Mar 2025 | Trial primary completion date: Jun 2023 --> Mar 2025 No abstract available
- || Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp, Hukyndra (adalimumab biosimilar) / Cipla, Alvotech, Stada, Teva, JAMP Pharma, YAS Holding, Yuflyma (adalimumab-aaty) / Celltrion, Hikma
Review, Journal: Navigating adalimumab biosimilars: an expert opinion. (Pubmed Central) - Nov 3, 2023
No abstract available The patent expiry of Humira in 2018 opened up the current European market to eight adalimumab biosimilars - (in alphabetical order) Amgevita, Amsparity, Hulio, Hukyndra, Hyrimoz, Idacio, Imraldi
- | Hulio (adalimumab-fkjp) / Fujifilm Kyowa Kirin Biologics, Biocon, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Hyrimoz (adalimumab-adaz) / Sandoz
Trial completion date, Trial primary completion date: Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE (clinicaltrials.gov) - Oct 31, 2023
P=N/A, N=50, Recruiting, Sponsor: NHS Greater Glasgow and Clyde
The patent expiry of Humira in 2018 opened up the current European market to eight adalimumab biosimilars - (in alphabetical order) Amgevita, Amsparity, Hulio, Hukyndra, Hyrimoz, Idacio, Imraldi Trial completion date: Dec 2025 --> Jul 2024 | Trial primary completion date: Dec 2025 --> Jul 2024
- Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Pharmacokinetic and Safety Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501 (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4133;
Results of this study demonstrate PK similarity between ABP 501-HCF (100 mg/mL) and ABP 501-LCF (50 mg/mL) following a single SC injection in healthy adult subjects. Immunogenicity and safety of ABP 501-HCF and ABP 501-LCF were also found to be similar.
- The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3801;
This could be due to upregulation of angiotensin-converting enzyme 2 (ACE2) receptors found in adipose tissues and impaired viral elimination as a result of disease-related and/ or obesity-induced blunted immune response and chronic inflammation [1]. Severe SARS-CoV-2 infections in this cohort were rare.Optimization of BMI may contribute to reducing risk and severity of COVID-19 infection.
- ||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
New P1 trial: Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira (clinicaltrials.gov) - Aug 16, 2023
P1, N=179, Completed, Sponsor: Amgen
- || Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Review, Journal: TNF? inhibitor biosimilar associated with polychondritis. A case-based review. (Pubmed Central) - Jul 17, 2023
Severe SARS-CoV-2 infections in this cohort were rare.Optimization of BMI may contribute to reducing risk and severity of COVID-19 infection. This report presents a 43-year-old man with psoriatic arthritis treated with ABP-501 (Amgevita), an adalimumab (ADA) biosimilar and who developed RP, 8
- | Journal: Expanded table: Some drugs for inflammatory bowel disease. (Pubmed Central) - Jul 11, 2023
This report presents a 43-year-old man with psoriatic arthritis treated with ABP-501 (Amgevita), an adalimumab (ADA) biosimilar and who developed RP, 8 No abstract available
- | Enrollment open: CAMEO: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease (clinicaltrials.gov) - Jul 10, 2023
P=N/A, N=900, Recruiting, Sponsor: Connecticut Children's Medical Center
No abstract available Not yet recruiting --> Recruiting
- | Hulio (adalimumab-fkjp) / Fujifilm Kyowa Kirin Biologics, Biocon, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Hyrimoz (adalimumab-adaz) / Sandoz
Enrollment open: Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE (clinicaltrials.gov) - Jul 10, 2023
P=N/A, N=50, Recruiting, Sponsor: NHS Greater Glasgow and Clyde
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
New P1 trial: A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants (clinicaltrials.gov) - Jun 18, 2023
P1, N=372, Completed, Sponsor: Amgen
- | Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Idacio (adalimumab-aacf) / Fresenius Kabi
Journal: Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience. (Pubmed Central) - Jun 9, 2023
Not yet recruiting --> Recruiting A cost-per responder analysis comparing adalimumab biosimilars MSB11022 (Idacio
- Monitoring adherence to subcutaneous biologics for IBD care using digital technology (Hall 11) - May 30, 2023 - Abstract #BSG2023BSG_210;
A cost-per responder analysis comparing adalimumab biosimilars MSB11022 (Idacio Aims and Following a successful NHS X bid for funding, a pilot proof of concept project to assess the feasibility and uptake of a digital technology (Health Beacon Digital Sharps Box
- Humira (adalimumab) / Eisai, AbbVie
Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response (Level 3 - Room 334+335+336) - Apr 24, 2023 - Abstract #WCD2023WCD_898;
Our study showed that switching HS patients from adalimumab originator to biosimilar ABP 501 does significantly affect treatment effectiveness. As a result, switching patients, who are on remission maintenance therapy, should be viewed critically
- | Trial completion date, Trial initiation date, Trial primary completion date: CAMEO: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease (clinicaltrials.gov) - Apr 24, 2023
P=N/A, N=900, Not yet recruiting, Sponsor: Connecticut Children's Medical Center
As a result, switching patients, who are on remission maintenance therapy, should be viewed critically Trial completion date: Apr 2029 --> Jul 2029 | Initiation date: Apr 2023 --> Jul 2023 | Trial primary completion date: Apr 2028 --> Jul 2028
- | Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
Observational data, Journal: Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. (Pubmed Central) - Mar 28, 2023
Our results provide a reassuring profile of effectiveness when switching from ADA originator to one of its biosimilars and between two different biosimilars. However, the worse outcome in PROs in patients initially treated with the bio-originator addresses the attention to a possible nocebo response, which should encourage comprehensive communication with patients.
- | New trial: CAMEO: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease (clinicaltrials.gov) - Mar 23, 2023
P=N/A, N=900, Not yet recruiting, Sponsor: Connecticut Children's Medical Center
- ||| Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Another level of complexity: Amgen's Humira biosimilar Amjevita hits the market with 2 different list prices https://t.co/OCBX9EmW58 (Twitter) - Feb 28, 2023
- || Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Fa il suo ingresso nel mercato degli Stati Uniti il primo biosimilare del celebre #Humira di @abbvie . Si tratta di #Amjevita, prodotto da @Amgen 👇 https://t.co/6kiC5dapL2 (Twitter) - Feb 6, 2023
- Humira (adalimumab) / Eisai, AbbVie
Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response – Data from the German HS Registry HSBest (Room 1) - Feb 2, 2023 - Abstract #EHSF2023EHSF_239;
Our study showed that switching HS patients from adalimumab originator to biosimilar ABP 501 does significantly affect treatment effectiveness. As a result, switching patients, who are on remission maintenance therapy, should be viewed critically.
- ||||| Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Biosimilar launch, FDA event, Pricing: Amgen launched its adalimumab biosimilar - Amjevita ( FDA approved in 2016), has 2 different discounts— 55% or 5% below Humira's (list $6,922/mo). Another report says Amjevita 40mg given q 2wk will cost $40,497 - $85,494 annually https://t.co/iGtJUa991N (Twitter) - Jan 31, 2023
- ||||| Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Biosimilar launch, FDA event, Pricing: Amgen launched an adalimumab biosimilar, Amjevita (FDA approved n 2016), at 2 different discounts— 55% or 5% below Humira's (list $6,922/mo). Another report says Amjevita 40mg given q 2wk will cost $40,497 - $85,494 annually https://t.co/615EBwHtpe https://t.co/KZOjYgHy0h (Twitter) - Jan 31, 2023
- || Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Amjevita first followed by several more adalimumab biosimilars later this year (Twitter) - Jan 31, 2023
- || What are🌼 Amjevita,🌼 Hadlima, 🌼Cyltezo, 🌼Yusimry,🌼 Hulio, 🌼Hyrimoz, and 🌼 Abrilada (Twitter) - Jan 24, 2023
- ||| Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Biosimilar launch: @Amgen launches #Amjevita on January 31, and payers have an awful lot to mull over with the adalimumab #biosimilar launches in 2023. https://t.co/jEmsYFmHKP #biosimilars (Twitter) - Jan 24, 2023
- ||||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Trial completion: A Comparative Study Between ABP 501 and Humira (clinicaltrials.gov) - Jan 5, 2023
P3, N=425, Completed, Sponsor: Amgen
As a result, switching patients, who are on remission maintenance therapy, should be viewed critically. Active, not recruiting --> Completed
- ||| Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan 2023 & 6 others (Pfizer, BI, Samsung, Coherus, Sandoz, Biocon) after July 2023. https://t.co/m8cdJgM7UC (Twitter) - Jan 4, 2023
- | Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Observational data, Journal: Continuous effectiveness and safety after a hospital-wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients. (Pubmed Central) - Dec 9, 2022
The objective of this study was to examine the maintenance of effect and safety after a hospital-wide switch for economic reasons from adalimumab originator Humira® to biosimilar Amgevita® in real-world rheumatoid arthritis (RA) patients and patient satisfaction with the switch...Also, there was no apparent evidence of increased side effects. Patients themselves were mostly satisfied with the switching experience.
- |||| Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan 2023 & 6 others (Pfizer, BI, Samsung, Coherus, Sandoz, Biocon) after July 2023. https://t.co/LH3MpT0o9O (Twitter) - Dec 5, 2022
- |||| Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Clinical: Treatment Persistence and Switching Patterns of an Adalimumab Biosimilar Dr. Julian Segan ( @JulianSegan) discusses Abstract 1425 at #ACR22 Abstract 1425: Treatment Persistence and Switching Patterns of AMGEVITA® in German Patients with RD https://t.co/MpNnrqYxGJ (Twitter) - Nov 29, 2022
- | Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Journal: Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBest. (Pubmed Central) - Oct 28, 2022
Our study showed that switching HS patients from ADAO to ABP 501 does significantly affect treatment effectiveness. Switching patients who are on remission maintenance therapy should be viewed critically.
- Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Humira (adalimumab) / Eisai, AbbVie
Adalimumab originator versus biosimilar adalimumab () - Oct 4, 2022 - Abstract #AGW2022AGW_465;
Familiarity with these factors is imperative to allow individualized prescribing so that the choice of agent can be individualized to the needs of the patient, prescriber, and health care service. Targeted prescribing according to patients' needs may improve adherence, treatment success, and quality of life.